Method of using cytoprotective alcohols to treat neural disease and neural injury |
| The present invention is grounded in the surprising discovery that hexacosanol and analogues and ... |
|
Methods of treating Parkinson's disease using melanin |
| OF THE INVENTION One aspect of the present invention relates to the treatment of a mammal having a ... |
|
Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds |
| OF THE INVENTION The present invention thus provides as a novel compound the R(+)-enantiomer of N-... |
|
L-DOPA ethyl ester to treat Parkinson's disease |
| OF THE INVENTION This invention provides a composition which comprises a pharmaceutically ... |
|
Episomal vector systems and related methods |
| The present invention provides papilloma virus episomal vector systems and methods for papilloma ... |
|
Method for treating Parkinson's disease employing an ATP-sensitive potassium channel blocker |
| What is claimed is: 1. A method for treating Parkinson's disease, which comprises administering ... |
|
Method of treatment of parkinson's disease |
| We claim: 1. A method of treatment of Parkinson's disease in a patient in need of such treatment, ... |
|
4-aminoethoxy indolone derivatives |
| What is claimed is: 1. A compound of the formula I: ##STR5## in which: Y is hydrogen, halogen or ... |
|
Genetically engineered cells that produce produce L. Dopa |
| In one aspect, the present invention provides a process of increasing the production of dopamine in ... |
|
C. elegans deletion mutants |
| What is claimed is: 1. A nematode having null mutations in hop-1 and sel-12, said nematode having a ... |
|
|
High molecular weight polymer-based prodrugs
| Details |
Inventors: Greenwald, Richard B.; Pendri, Annapurna; Zhao, Hong;
Assignee: Enzon, Inc. (Piscataway, NJ)
Primary Examiner: Trinh; Ba K.
Assistant Examiner:
Attorney, Agent or Firm: Roberts & Mercanti, LLP
The present invention is directed compositions of the formula: ##STR1## wherein: D is a residue of a biologically active moiety; X is an electron withdrawing group; Y and Y' are independently O or S; (n) is zero (0) or a positive integer, preferably from 1 to about 12; R.sub.1 and R.sub.2 are independently selected from the group consisting of H, C.sub.1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls and substituted C.sub.1-6 alkyls; R.sub.3 is a substantially non-antigenic polymer, C.sub.1-12 straight or branched alkyl or substituted alkyl, C.sub.5-8 cycloalkyl or substituted cycloalkyl, carboxyalkyl, carboalkoxy alkyl, dialkylaminoalkyl, phenylalkyl, phenylaryl or ##STR2## R.sub.4 and R.sub.5 are independently selected from the group consisting of H, C.sub.1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls, and substituted C.sub.1-6 alkyls or jointly form a cyclic C.sub.5 -C.sub.7 ring. In preferred embodiments, the prodrugs contain a polyethylene glycol having a molecular weight of at least about 20,000. |
|
DETAILED DESCRIPTION OF THE INVENTION A. THE PRODRUGS In most aspects of the invention, the prodrug compositions of the present invention contain hydrolyzable linkages between the polymer portion and a biologically active moiety derived from a biologically active moiety or nucleophile, i. e. native or unmodified drug. These linkages are preferably ester linkages designed to hydrolyze at a rate which generates sufficient amounts of the biologically active parent compound in a suitable time period so that therapeutic levels of the parent therapeutic moiety or moieties are delivered prior to excretion from or inactivation by the body. The term "sufficient amounts" for purposes of the present invention shall mean an amount which achieves a therapeutic effect as such effect is understood by those of ordinary skill in the art. In one preferred embodiment of the invention, the prodrug compositions of the invention comprise the formula set forth below: ##STR6## wherein: D is a residue of a biologically active moiety; X is an electron withdrawing group; Y and Y' are independently O or S; (n) is zero (0) or a positive integer, preferably from 1 to about 12; R. sub. 1 and R. sub. 2 are independently selected from the group consisting of H, C. sub. 1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls and substituted C. sub. 1-6 alkyls; p1 R. sub. 3 is a substantially non-antigenic polymer, C. sub. 1-12 straight or branched alkyl or substituted alkyl, C. sub. 5-8 cycloalkyl or substituted cycloalkyl, carboxyalkyl, carboalkoxy alkyl, dialkylaminoalkyl, phenylalkyl, phenylaryl or ##STR7## R. sub. 4 and R. sub. 5 are independently selected from the group consisting of H, C. sub. 1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls, and substituted C. sub. 1-6 alkyls or jointly form a cyclic C. sub. 5 -C. sub. 7 ring. Preferably, the polymer portion, designated R. sub. 3 herein, is further substituted with a terninal capping moiety (Z) which is distal to the primary linkage attaching D to the polymer
|
| Related patents |
|
|
Non-antigenic amine derived polymers and polymer conjugates
In one aspect of the invention, there are provided amine-based polymer intermediates having the formula: R--B (I) wherein (R) is a water-soluble, substantially non-...
|
|
|
Biodegradable high molecular weight polymeric linkers and their conjugates
The present invention includes compounds of the formula: (D).sub.n --M--(R.sub.1).sub.m (I) wherein (m) and (n) independently selected positive integers, preferably from ...
|
|
|
Modified polypeptides with high activity and reduced allergenicity
OF THE INVENTION The modified polypeptide of the present invention is represented by the formula: A-B.sub.n containing, as essential components, a enzyme, A, and a ...
|
|
|
Poly(ethylene glycol) derivatives with proximal reactive groups
OF THE INVENTION The terms "group," "functional group," "moiety," "active moiety," "reactive site," reactive group" and "reactive moiety" are used in the art and herein ...
|
|
|
Devices for cloaking transplanted cells
A variety of devices can be used to contain or cloak a source of a therapeutic substance, often cells, which source provides the substance to a host or recipient subject....
|
|
|
Terminally-branched polymeric linkers and polymeric conjugates containing the same
In one aspect of the invention, compounds of Formula (I) are provided: ##STR6## wherein: J is ##STR7## E.sub.1-4 are independently selected from the group consisting of ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising rectally administering to a patient a ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A method of enhancing the rate of absorption of a rectally administered composition comprising a therapeutically effective dosage amount of an ...
|
|
|
Rectally absorbable form of L-dopa
What is claimed is: 1. A pharmaceutical composition for enhancing rectal absorption of L-dopa by administering a formulation comprising a therapeutically effective ...
|
|
|
Method to treat Parkinsons disease
I claim: 1. The method of treatment of Parkinson's disease and related neurological syndromes which consists of administering by the oral or sublingual route to a ...
|
|
|